Interphex China-API China Exhibition Attract 30,000
The co-located Interphex China and API China exhibitions, held November 13–15 in Shenzhen-just across the river from Hong Kong-attracted 30,000 dealers, buyers, and sellers of ingredients, intermediates, excipients, and processing and packaging machinery.
The co-located Interphex China and API China exhibitions, held November 13–15 in Shenzhen-just across the river from Hong Kong-attracted 30,000 dealers, buyers, and sellers of ingredients, intermediates, excipients, and processing and packaging machinery.
The show-the 59th edition of API China and the third edition of Interphex China-provides a window into the dynamic Chinese pharmaceutical industry. The domestic Chinese pharmaceutical market is forecast to grow by more than 15% a year over the next three years. At the same time, Chinese manufacturers are increasing their exports of raw materials, excipients, and active pharmaceutical ingredients to pharmaceutical companies worldwide, including to developed countries in the West. Exhibitors in the API section of the show reflected both the size and diversity of the Chinese industry, ranging from suppliers of traditional Chinese medicines for the domestic market to companies providing high quality ingredients for Western manufacturers.
Managers at several exporting companies exhibiting at the show acknowledged that Western quality standards are higher than Chinese requirements, but noted that things are changing. “Chinese standards are constantly getting tougher,” said Zeng Huan Qun, vice president of Cheng Yi Pharmaceutical Co, an API and intermediates manufacturer based in Zhejiang, whose booth displayed enlarged copies of approval letters from the US FDA and other Western regulatory agencies. Zeng also noted that more and more local companies are rising to the challenge of meeting higher quality standards. “Two other companies in our province recently passed US FDA inspections,” he said.
Exhibitors at the Interphex portion of the show are betting that as China’s pharmaceutical manufacturing industry grows, the demand for equipment-particularly high quality equipment-will grow with it. Pall Life Sciences is taking its participation in the Chinese market one step further, by offering expertise as well as tools. At the event, Pall announced the launch of its Technical Innovation Center in Shanghai, which will provide technical support, validation services, and professional training for its customers. “We were pleased that our technical and scientific staff received numerous inquiries [about the center of excellence] at the show,” said Ian Sellick, PhD, director of marketing for Pall Life Sciences.
This is this third co-location of the two shows, which are produced by Reed Sinopharm Exhibitions, a joint venture between Reed Exhibitions and the Chinese state-owned company China National Pharmaceutical Group (Sinopharm). The next edition of API China-Interphex China will be held from May 20–22, 2008, in Dalian.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
Top 10 Cleanroom Problems That Can Be Prevented via Preventative Maintenance (May 2025)
May 16th 2025Cleanrooms require strict environmental control to maintain sterility, prevent contamination, and ensure seamless operations. Without a proactive preventative maintenance (PM) program, various issues can arise, leading to costly downtime, contamination risks, and operational inefficiencies. Below are ten common cleanroom problems that can be effectively mitigated through proper PM practices.
